Keyword: Lars Fruergaard Jorgensen
Novo Nordisk rolled out more data for its next great hope: oral semaglutide, which would be the only pill in a hotly competitive GLP-1 class.
The approval case for Novo Nordisk’s oral diabetes candidate keeps on building, this time with new data in patients with kidney troubles.
Novo Nordisk expects basal insulin prices to sink even further next year—but that shouldn’t surprise investors too much, the company’s CEO says.
Let’s just say it hasn’t been a great week for Novo Nordisk.
Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.
Novo Nordisk, fighting competition to its blockbuster Victoza, just posted data on a follow-up drug that gives it an edge over archrival Trulicity.
While pricing challenges hit drugmakers in diabetes, Novo Nordisk CEO Lars Fruergaard Jorgensen said portfolio and execution can drive growth.
Denmark’s Novo Nordisk surprised some folks when it selected Lars Fruergaard Jorgensen as its new CEO. Now Jorgensen has a new strategy for growth.
Someone entirely new at Novo Nordisk will have to deal with big challenges in its largest market after its head of North American operations quit.
Novo Nordisk was already worried about the U.S., what with stepped-up competition from new rivals and hardball pricing tactics by payers. But it’s even more worried now. Why? U.S. politics.